Sánchez-Montes Cristina, Ortiz Vicente, Bastida Guillermo, Rodríguez Ester, Yago María, Beltrán Belén, Aguas Mariam, Iborra Marisa, Garrigues Vicente, Ponce Julio, Nos Pilar
Cristina Sánchez-Montes, Vicente Ortiz, Guillermo Bastida, Ester Rodríguez, María Yago, Belén Beltrán, Mariam Aguas, Marisa Iborra, Vicente Garrigues, Julio Ponce, Pilar Nos, Gastroenterology Unit, Hospital Universitari i Politécnic La Fe, 46026 Valencia, Spain.
World J Gastroenterol. 2014 Oct 14;20(38):13999-4003. doi: 10.3748/wjg.v20.i38.13999.
To investigate the influence of thiopurines and biological drugs on the presence of small intestinal bacterial overgrowth (SIBO) in patients with inactive Crohn's disease (CD).
This was a prospective study in patients with CD in remission and without corticosteroid treatment, included consecutively from 2004 to 2010. SIBO was investigated using the hydrogen glucose breath test.
One hundred and seven patients with CD in remission were included. Almost 58% of patients used maintenance immunosuppressant therapy and 19.6% used biological therapy. The prevalence of SIBO was 16.8%. No association was observed between SIBO and the use of thiopurine Immunosuppressant (12/62 patients), administration of biological drugs (2/21 patients), or with double treatment with an anti-tumor necrosis factor drugs plus thiopurine (1/13 patients). Half of the patients had symptoms that were suggestive of SIBO, though meteorism was the only symptom that was significantly associated with the presence of SIBO on univariate analysis (P < 0.05). Multivariate analysis revealed that the presence of meteorism and a fistulizing pattern were associated with the presence of SIBO (P < 0.05).
Immunosuppressants and/or biological drugs do not induce SIBO in inactive CD. Fistulizing disease pattern and meteorism are associated with SIBO.
研究硫唑嘌呤和生物制剂对缓解期克罗恩病(CD)患者小肠细菌过度生长(SIBO)的影响。
这是一项对2004年至2010年连续纳入的缓解期CD患者且未接受皮质类固醇治疗的前瞻性研究。采用氢葡萄糖呼气试验检测SIBO。
纳入107例缓解期CD患者。近58%的患者使用维持性免疫抑制治疗,19.6%的患者使用生物治疗。SIBO的患病率为16.8%。未观察到SIBO与硫唑嘌呤免疫抑制剂的使用(62例患者中的12例)、生物制剂的使用(21例患者中的2例)或抗肿瘤坏死因子药物加硫唑嘌呤联合治疗(13例患者中的1例)之间存在关联。一半的患者有提示SIBO的症状,尽管在单因素分析中,腹胀是唯一与SIBO存在显著相关的症状(P<0.05)。多因素分析显示,腹胀的存在和瘘管形成模式与SIBO的存在相关(P<0.05)。
免疫抑制剂和/或生物制剂不会在缓解期CD患者中诱发SIBO。瘘管形成疾病模式和腹胀与SIBO相关。